MARKET NEWS

Novavax’s NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial
SPI Pharma Expands Product Portfolio to Support Development, Manufacture & Administration of Oral Dosage Forms
Positive Update on the Development of New XF‐Platform Drug Formulations
Rafael Pharmaceuticals Enrolls More Than 75% of Patients Needed for Pivotal Phase 3 Trial
Origin Files Patent Application to Protect its Proposed Treatment for Viral & Bacterial Respiratory Infections
Immunogenesis Contracts ProBioGen for Development & Large-Scale Manufacturing Services

  FEATURED EDITORIAL

 

  COMPANY PROFILE

Pfanstiehl is a global leader in the manufacture of cGMP high purity, low endotoxin, low metal injectable-grade excipients and biopharmaceutical components for upstream bioprocessing, downstream formulation, and specialty applications. In addition, Pfanstiehl is a leading contract development and manufacturing organization (CDMO) specializing in the isolation, purification, custom synthesis, and scale-up development of small molecule Active Pharmaceutical Ingredients (APIs), in gram to multi-ton commercial quantities. While most ingredient manufacturers or resellers focus on other industries, such as food, cosmetics, agriculture, and/or nutritional supplements, offering only a subset of ‘pharma- grade’ ingredients, Pfanstiehl is Pharma Grade through and through. Click here for more.

 

Looking for an experienced and committed steriles CDMO? Look no further than Pii. Pii has a strong pedigree of scientific know-how and regulatory experience across a range of dosage forms, including capacity for aseptic fill-finish. Our commitment to this market and our capabilities have grown further with investment in a new, fully-robotic aseptic filling line. With expanded capacity for small to medium-batch production of commercial and clinical materials, we are eager to discuss your needs, so we can help advance your sterile product. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Covid-19 Outbreak in China Threatens Biopharma In-House Manufacturing

Covid-19 Outbreak in China Threatens Biopharma In-House Manufacturing

With several mega cap biopharma companies having their vital manufacturing steps in Chinese facilities, the novel coronavirus (Covid-19) outbreak is putting the complicated global biopharma industry’s supply….

Lonza Launches New TheraPEAK SfAAV Medium to Boost & Optimize the Production of AAV in Sf9 Insect Cells

Lonza Launches New TheraPEAK SfAAV Medium to Boost & Optimize the Production of AAV in Sf9 Insect Cells

Lonza recently announced the launch of the TheraPEAK SfAAV Medium, the first chemically defined, non-animal origin medium designed specifically for the production of….

Derm-Biome Pharmaceuticals Reports Positive Results From a Preclinical Study

Derm-Biome Pharmaceuticals Reports Positive Results From a Preclinical Study

Derm-Biome Pharmaceuticals, Inc. recently announced that one of its topical drugs produced significant, and dose dependent inhibitory effects in a well established mouse model of….

Akers Biosciences Acquires Licenses to Coronavirus Vaccine Candidate From Premas Biotech

Akers Biosciences Acquires Licenses to Coronavirus Vaccine Candidate From Premas Biotech

Akers Biosciences, Inc. recently announced it has acquired a licensing agreement with Premas Biotech, under which Akers will in-license a novel coronavirus vaccine candidate under development by…..

WPD Pharmaceuticals Partners With CNS Pharmaceuticals on Drug Development for Coronavirus & Other Antiviral Indications

WPD Pharmaceuticals Partners With CNS Pharmaceuticals on Drug Development for Coronavirus & Other Antiviral Indications

WPD Pharmaceuticals Inc. recently announced it has entered into a development agreement with CNS Pharmaceuticals, Inc. for the development of……

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

April 8 – Excipients
April 15 – Prefilled Syringes